Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review

Han, Zhaoguo; Wu, Yongyi; Wang, Kai; Xiao, Yadi; Cheng, Zhen; Sun, Xilin; Shen, Baozhong

doi:10.1186/s13550-017-0286-z

EJNMMI Research

Table 1 Representative molecular imaging agents developed for c-MET imaging in cancer

From: Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review

Name	Nature	Molecular weight (kDa)	Targeted area	Tumor model	Tumor uptake	T/C	Imaging technique	Time point	Clin
⁶⁴Cu-NOTA-rh-HGF	rh-ligand	~90	Extracellular	U87MG	6.8 ± 1.8%ID/g	T/M =13.5 ± 6.1	PET	9 h p.i.	No
¹²⁵I-mAb	mAb	~150	Extracellular	S114	–	T/TB = 0.37	Gamma camera	3 days p.i.	No
¹²⁵I-Met3	mAb	~150	Extracellular	S114, SK-LMS-1/HGF	18.6 ± 2.1%EIA, 7.2 ± 2.2%EIA	T/TB = 0.32 ± 0.13, T/TB = 0.168 ± 0.076	Gamma camera	3 days p.i., 6 days p.i.	No
¹²⁵I-Met5	mAb	~150	Extracellular	SK-LMS-1/HGF	13.3 ± 7.6%EIA,	T/TB = 0.146 ± 0.097	Gamma camera	1 day p.i.	No
¹²⁵I-hFab-Met-1	Fab fragment	~60	Extracellular	SK-LMS-1/HGF	6%EIA	–	Gamma camera	5 h p.i.	No
¹²⁵I-MET4	mAb	~150	Extracellular	SK-LMS-1/HGF	–	–	Gamma camera	3 days p.i.	No
⁸⁹Zr-DN30	mAb	~150	Extracellular	GTL-16	19.6 ± 3.3%ID/g	T/M = 17.5	PET	3 days p.i	No
⁸⁹Zr-df-onartuzumab	mAb	~99	Extracellular	MKN-45	23%ID/g	T/M = 27	PET	3 days p.i	No
⁸⁹Zr-DFO-H2cys-diabody	scFv	~55	Extracellular	Hcc827-GR6	3.4 ± 0.3%ID/g	T/M =27 ± 14	PET	44 h p.i.	No
Ms20-QD	scFv	~25	Extracellular	H1993	–	T/T_n = 4.3	NIRfluorescence	24 h p.i.	No
anti-MET-Gd-DTPA-albumin	mAb	~150	Extracellular	C6	–	SIC(T/T_n) ≈ 5	MRI	3 h p.i.	No
SPIO-anti-c-MET	PcAb	~150	Extracellular	CDAA-HCC	–	SIC(T/T_n) ≈ 2	MRI	1.5 h p.i.	No
¹²⁵I-Met-pep1	Peptide	~1.5	Extracellular	SK-LMS-1/HGF	5%EIA,	–	Gamma camera	4 h p.i.	No
¹²⁵I-cMBP-GGG	Peptide	~1.9	Extracellular	U87MG	7.05 ± 1.2%ID/g	T/Bl = 2.94	SPECT	4 h p.i.	No
cMBP-AOC-Cy5.5	Peptide	~2.8	Extracellular	U87MG	–	T/M =33.711 ± 3.34	NIRfluorescence	5 h p.i.	No
GE-137	Peptide	~4.2	Extracellular	SKOv3	–	T/Ba = 1.6	NIRfluorescence	3 h p.i.	Yes
¹⁸F-AH113804	Peptide	~3.2	Extracellular	HCC1954	1.5 ± 0.2%ID/ml	T/M ≈ 2	PET	1 h p.i.	No
^99mTc-AH113018	Peptide	~3.2	Extracellular	MKN-45	10.1 ± 1.5%ID/g	T/M =55.2 ± 13.4	SPECT	1.5 h p.i.	No
⁸⁹Zr-PRS-110	s-protein	57	Extracellular	H441	7.5 ± 3.4%ID/g	T:M = 29	PET	48 h p.i.	No
¹¹C- SU11274	smTKI	~0.6	Intracellular	H1975	SUV = 0.45	T/T_N = 2.6	PET	1.3 h p.i.	No

Tumor model major positive tumor model, Tumor uptake highest tumor uptake in major positive tumor model, T/C tumor control area activity ratio, Time point optimal imaging time point, Clin clinical transformation, %EIA percentage of estimated injected activity, SUV standard uptake value, T/M tumor to muscle, T/TB tumor to total body, T/T _n tumor to tumor with non-specific probe, SIC signal intensity changes, T/Bl tumor to blood, T/Ba tumor to background fluorescence, T/T _N tumor to negative tumor

Back to article page